

FIRST REGULAR SESSION

# HOUSE BILL NO. 572

## 96TH GENERAL ASSEMBLY

---

INTRODUCED BY REPRESENTATIVE POLLOCK.

1571L.011

D. ADAM CRUMBLISS, Chief Clerk

---

### AN ACT

To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to controlled substances, with an existing penalty provision.

---

*Be it enacted by the General Assembly of the state of Missouri, as follows:*

Section A. Section 195.017, RSMo, is repealed and one new section enacted in lieu thereof, to be known as section 195.017, to read as follows:

195.017. 1. The department of health and senior services shall place a substance in Schedule I if it finds that the substance:

(1) Has high potential for abuse; and

(2) Has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision.

2. Schedule I:

(1) The controlled substances listed in this subsection are included in Schedule I;

(2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

(a) Acetyl-alpha-methylfentanyl;

(b) Acetylmethadol;

(c) Allylprodine;

(d) Alphacetylmethadol;

(e) Alphameprodine;

(f) Alphamethadol;

(g) Alpha-methylfentanyl;

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

- 18 (h) Alpha-methylthiofentanyl;
- 19 (i) Benzethidine;
- 20 (j) Betacetylmethadol;
- 21 (k) Beta-hydroxyfentanyl;
- 22 (l) Beta-hydroxy-3-methylfentanyl;
- 23 (m) Betameprodine;
- 24 (n) Betamethadol;
- 25 (o) Betaprodine;
- 26 (p) Clonitazene;
- 27 (q) Dextromoramide;
- 28 (r) Diampromide;
- 29 (s) Diethylthiambutene;
- 30 (t) Difenoxin;
- 31 (u) Dimenoxadol;
- 32 (v) Dimepheptanol;
- 33 (w) Dimethylthiambutene;
- 34 (x) Dioxaphetyl butyrate;
- 35 (y) Dipipanone;
- 36 (z) Ethylmethylthiambutene;
- 37 (aa) Etonitazene;
- 38 (bb) Etoxeridine;
- 39 (cc) Furethidine;
- 40 (dd) Hydroxypethidine;
- 41 (ee) Ketobemidone;
- 42 (ff) Levomoramide;
- 43 (gg) Levophenacymorphan;
- 44 (hh) 3-Methylfentanyl;
- 45 (ii) 3-Methylthiofentanyl;
- 46 (jj) Morpheridine;
- 47 (kk) MPPP;
- 48 (ll) Noracymethadol;
- 49 (mm) Norlevorphanol;
- 50 (nn) Normethadone;
- 51 (oo) Norpipanone;
- 52 (pp) Para-fluorofentanyl;
- 53 (qq) PEPAP;

- 54 (rr) Phenadoxone;
- 55 (ss) Phenampromide;
- 56 (tt) Phenomorphan;
- 57 (uu) Phenoperidine;
- 58 (vv) Piritramide;
- 59 (ww) Proheptazine;
- 60 (xx) Properidine;
- 61 (yy) Propiram;
- 62 (zz) Racemoramide;
- 63 (aaa) Thiofentanyl;
- 64 (bbb) Tilidine;
- 65 (ccc) Trimeperidine;

66 (3) Any of the following opium derivatives, their salts, isomers and salts of isomers  
67 unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers  
68 is possible within the specific chemical designation:

- 69 (a) Acetorphine;
- 70 (b) Acetyldihydrocodeine;
- 71 (c) Benzylmorphine;
- 72 (d) Codeine methylbromide;
- 73 (e) Codeine-N-Oxide;
- 74 (f) Cyprenorphine;
- 75 (g) Desomorphine;
- 76 (h) Dihydromorphine;
- 77 (i) Drotebanol;
- 78 (j) Etorphine (except hydrochloride salt);
- 79 (k) Heroin;
- 80 (l) Hydromorphanol;
- 81 (m) Methyldesorphine;
- 82 (n) Methyldihydromorphine;
- 83 (o) Morphine methylbromide;
- 84 (p) Morphine methylsulfonate;
- 85 (q) Morphine-N-Oxide;
- 86 (r) Myorphine;
- 87 (s) Nicocodeine;
- 88 (t) Nicomorphine;
- 89 (u) Normorphine;

- 90 (v) Pholcodine;
- 91 (w) Thebacon;
- 92 (4) Any material, compound, mixture or preparation which contains any quantity of the
- 93 following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically
- 94 excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within
- 95 the specific chemical designation:
- 96 (a) 4-bromo-2, 5-dimethoxyamphetamine;
- 97 (b) 4-bromo-2, 5-dimethoxyphenethylamine;
- 98 (c) 2,5-dimethoxyamphetamine;
- 99 (d) 2,5-dimethoxy-4-ethylamphetamine;
- 100 (e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
- 101 (f) 4-methoxyamphetamine;
- 102 (g) 5-methoxy-3,4-methylenedioxyamphetamine;
- 103 (h) 4-methyl-2, 5-dimethoxyamphetamine;
- 104 (i) 3,4-methylenedioxyamphetamine;
- 105 (j) 3,4-methylenedioxymethamphetamine;
- 106 (k) 3,4-methylenedioxy-N-ethylamphetamine;
- 107 (l) N-hydroxy-3, 4-methylenedioxyamphetamine;
- 108 (m) 3,4,5-trimethoxyamphetamine;
- 109 (n) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine, its isomers, salts, and salts of
- 110 isomers;
- 111 (o) Alpha-ethyltryptamine;
- 112 (p) Alpha-methyltryptamine;
- 113 (q) Bufotenine;
- 114 (r) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-
- 115 6a,7,10,10 a-tetrahydrobenzo[c]chromen-1-ol;
- 116 (s) Diethyltryptamine;
- 117 (t) Dimethyltryptamine;
- 118 (u) 5-methoxy-N,N-diisopropyltryptamine;
- 119 (v) Ibogaine;
- 120 (w) Indole, or 1-butyl-3(1-naphthoyl)indole;
- 121 (x) Indole, or 1-pentyl-3(1-naphthoyl)indole;
- 122 (y) Lysergic acid diethylamide;
- 123 (z) Marijuana or marihuana;
- 124 (aa) Mescaline;
- 125 (bb) Parahexyl;

- 126 (cc) Peyote, to include all parts of the plant presently classified botanically as  
127 Lophophora Williamsii Lemaire, whether growing or not; the seeds thereof; any extract from any  
128 part of such plant; and every compound, manufacture, salt, derivative, mixture or preparation of  
129 the plant, its seed or extracts;
- 130 (dd) Phenol, CP 47, 497 & homologues, or 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-  
131 methyloctan-2-yl)phenol), where side chain n=5, and homologues where side chain n=4,6, or 7;
- 132 (ee) N-ethyl-3-piperidyl benzilate;
- 133 (ff) N-methyl-3-piperidyl benzilate;
- 134 (gg) Psilocybin;
- 135 (hh) Psilocyn;
- 136 (ii) Tetrahydrocannabinols naturally contained in a plant of the genus Cannabis (cannabis  
137 plant), as well as synthetic equivalents of the substances contained in the cannabis plant, or in  
138 the resinous extractives of such plant, or synthetic substances, derivatives, and their isomers with  
139 similar chemical structure and pharmacological activity to those substances contained in the  
140 plant, such as the following:
- 141 a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;
- 142 b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;
- 143 c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;
- 144 d. Any compounds of these structures, regardless of numerical designation of atomic  
145 positions covered;
- 146 (jj) Ethylamine analog of phencyclidine;
- 147 (kk) Pyrrolidine analog of phencyclidine;
- 148 (ll) Thiophene analog of phencyclidine;
- 149 (mm) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
- 150 (nn) Salvia divinorum;
- 151 (oo) Salvinorin A;
- 152 (5) Any material, compound, mixture or preparation containing any quantity of the  
153 following substances having a depressant effect on the central nervous system, including their  
154 salts, isomers and salts of isomers whenever the existence of these salts, isomers and salts of  
155 isomers is possible within the specific chemical designation:
- 156 (a) Gamma-hydroxybutyric acid;
- 157 (b) Mecloqualone;
- 158 (c) Methaqualone;
- 159 (6) Any material, compound, mixture or preparation containing any quantity of the  
160 following substances having a stimulant effect on the central nervous system, including their  
161 salts, isomers and salts of isomers:

- 162 (a) Aminorex;
- 163 (b) N-benzylpiperazine;
- 164 (c) Cathinone;
- 165 (d) Fenethylamine;
- 166 (e) Methcathinone;
- 167 (f) **Methylenedioxypropylamphetamine or [(MDPV) (1-(1,3-Benzodioxol-5-yl)-2-(1-**
- 168 **pyrrolidinyl)-1-pentanone]**;
- 169 [(f)] (g) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-
- 170 oxazolamine);
- 171 [(g)] (h) N-ethylamphetamine;
- 172 [(h)] (i) N,N-dimethylamphetamine;
- 173 (7) A temporary listing of substances subject to emergency scheduling under federal law
- 174 shall include any material, compound, mixture or preparation which contains any quantity of the
- 175 following substances:
- 176 (a) N-(1-benzyl-4-piperidyl)-N-phenylpropanamide (benzylfentanyl), its optical isomers,
- 177 salts and salts of isomers;
- 178 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its
- 179 optical isomers, salts and salts of isomers;
- 180 (8) Khat, to include all parts of the plant presently classified botanically as *catha edulis*,
- 181 whether growing or not; the seeds thereof; any extract from any part of such plant; and every
- 182 compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed or extracts.
- 183 3. The department of health and senior services shall place a substance in Schedule II
- 184 if it finds that:
- 185 (1) The substance has high potential for abuse;
- 186 (2) The substance has currently accepted medical use in treatment in the United States,
- 187 or currently accepted medical use with severe restrictions; and
- 188 (3) The abuse of the substance may lead to severe psychic or physical dependence.
- 189 4. The controlled substances listed in this subsection are included in Schedule II:
- 190 (1) Any of the following substances whether produced directly or indirectly by extraction
- 191 from substances of vegetable origin, or independently by means of chemical synthesis, or by
- 192 combination of extraction and chemical synthesis:
- 193 (a) Opium and opiate and any salt, compound, derivative or preparation of opium or
- 194 opiate, excluding apomorphine, thebaine-derived butorphanol, dextropropoxyphene, nalbuphine,
- 195 nalmefene, naloxone and naltrexone, and their respective salts but including the following:
- 196 a. Raw opium;
- 197 b. Opium extracts;

- 198 c. Opium fluid;
- 199 d. Powdered opium;
- 200 e. Granulated opium;
- 201 f. Tincture of opium;
- 202 g. Codeine;
- 203 h. Ethylmorphine;
- 204 i. Etorphine hydrochloride;
- 205 j. Hydrocodone;
- 206 k. Hydromorphone;
- 207 l. Metopon;
- 208 m. Morphine;
- 209 n. Oxycodone;
- 210 o. Oxymorphone;
- 211 p. Thebaine;
- 212 (b) Any salt, compound, derivative, or preparation thereof which is chemically
- 213 equivalent or identical with any of the substances referred to in this subdivision, but not
- 214 including the isoquinoline alkaloids of opium;
- 215 (c) Opium poppy and poppy straw;
- 216 (d) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
- 217 any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical
- 218 with any of these substances, but not including decocainized coca leaves or extractions which
- 219 do not contain cocaine or ecgonine;
- 220 (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid
- 221 or powder form which contains the phenanthrene alkaloids of the opium poppy);
- 222 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
- 223 of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within
- 224 the specific chemical designation, dextropropoxyphene excepted:
- 225 (a) Alfentanil;
- 226 (b) Alphaprodine;
- 227 (c) Anileridine;
- 228 (d) Bezitramide;
- 229 (e) Bulk dextropropoxyphene;
- 230 (f) Carfentanil;
- 231 (g) Dihydrocodeine;
- 232 (h) Diphenoxylate;
- 233 (i) Fentanyl;

- 234 (j) Isomethadone;
- 235 (k) Levo-alphaacetylmethadol;
- 236 (l) Levomethorphan;
- 237 (m) Levorphanol;
- 238 (n) Metazocine;
- 239 (o) Methadone;
- 240 (p) Meperidine;
- 241 (q) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
- 242 (r) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane--carboxylic
- 243 acid;
- 244 (s) Pethidine (meperidine);
- 245 (t) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 246 (u) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 247 (v) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 248 (w) Phenazocine;
- 249 (x) Piminodine;
- 250 (y) Racemethorphan;
- 251 (z) Racemorphan;
- 252 (aa) Remifentanil;
- 253 (bb) Sufentanil;
- 254 (cc) Tapentadol;
- 255 (3) Any material, compound, mixture, or preparation which contains any quantity of the
- 256 following substances having a stimulant effect on the central nervous system:
- 257 (a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 258 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;
- 259 (c) Methamphetamine, its salts, isomers, and salts of its isomers;
- 260 (d) Phenmetrazine and its salts;
- 261 (e) Methylphenidate;
- 262 (4) Any material, compound, mixture, or preparation which contains any quantity of the
- 263 following substances having a depressant effect on the central nervous system, including its salts,
- 264 isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers
- 265 is possible within the specific chemical designation:
- 266 (a) Amobarbital;
- 267 (b) Glutethimide;
- 268 (c) Pentobarbital;
- 269 (d) Phencyclidine;

- 270 (e) Secobarbital;
- 271 (5) Any material or compound which contains any quantity of nabilone;
- 272 (6) Any material, compound, mixture, or preparation which contains any quantity of the
- 273 following substances:
- 274 (a) Immediate precursor to amphetamine and methamphetamine: Phenylacetone;
- 275 (b) Immediate precursors to phencyclidine (PCP):
- 276 a. 1-phenylcyclohexylamine;
- 277 b. 1-piperidinocyclohexanecarbonitrile (PCC);
- 278 (7) Any material, compound, mixture, or preparation which contains any quantity of the
- 279 following alkyl nitrites:
- 280 (a) Amyl nitrite;
- 281 (b) Butyl nitrite.
- 282 5. The department of health and senior services shall place a substance in Schedule III
- 283 if it finds that:
- 284 (1) The substance has a potential for abuse less than the substances listed in Schedules
- 285 I and II;
- 286 (2) The substance has currently accepted medical use in treatment in the United States;
- 287 and
- 288 (3) Abuse of the substance may lead to moderate or low physical dependence or high
- 289 psychological dependence.
- 290 6. The controlled substances listed in this subsection are included in Schedule III:
- 291 (1) Any material, compound, mixture, or preparation which contains any quantity of the
- 292 following substances having a potential for abuse associated with a stimulant effect on the
- 293 central nervous system:
- 294 (a) Benzphetamine;
- 295 (b) Chlorphentermine;
- 296 (c) Clortermine;
- 297 (d) Phendimetrazine;
- 298 (2) Any material, compound, mixture or preparation which contains any quantity or salt
- 299 of the following substances or salts having a depressant effect on the central nervous system:
- 300 (a) Any material, compound, mixture or preparation which contains any quantity or salt
- 301 of the following substances combined with one or more active medicinal ingredients:
- 302 a. Amobarbital;
- 303 b. Secobarbital;
- 304 c. Pentobarbital;
- 305 (b) Any suppository dosage form containing any quantity or salt of the following:

- 306 a. Amobarbital;  
307 b. Secobarbital;  
308 c. Pentobarbital;  
309 (c) Any substance which contains any quantity of a derivative of barbituric acid or its  
310 salt;  
311 (d) Chlorhexadol;  
312 (e) Embutramide;  
313 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in  
314 a drug product for which an application has been approved under Section 505 of the federal  
315 Food, Drug, and Cosmetic Act;  
316 (g) Ketamine, its salts, isomers, and salts of isomers;  
317 (h) Lysergic acid;  
318 (i) Lysergic acid amide;  
319 (j) Methyprylon;  
320 (k) Sulfondiethylmethane;  
321 (l) Sulfonethylmethane;  
322 (m) Sulfonmethane;  
323 (n) Tiletamine and zolazepam or any salt thereof;  
324 (3) Nalorphine;  
325 (4) Any material, compound, mixture, or preparation containing limited quantities of any  
326 of the following narcotic drugs or their salts:  
327 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not more than  
328 ninety milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid  
329 of opium;  
330 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not more than  
331 ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized  
332 therapeutic amounts;  
333 (c) Not more than three hundred milligrams of hydrocodone per one hundred milliliters  
334 or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an  
335 isoquinoline alkaloid of opium;  
336 (d) Not more than three hundred milligrams of hydrocodone per one hundred milliliters  
337 or not more than fifteen milligrams per dosage unit, with one or more active nonnarcotic  
338 ingredients in recognized therapeutic amounts;  
339 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters or not more  
340 than ninety milligrams per dosage unit, with one or more active nonnarcotic ingredients in  
341 recognized therapeutic amounts;

342 (f) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters  
343 or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic  
344 ingredients in recognized therapeutic amounts;

345 (g) Not more than five hundred milligrams of opium per one hundred milliliters or per  
346 one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more  
347 active nonnarcotic ingredients in recognized therapeutic amounts;

348 (h) Not more than fifty milligrams of morphine per one hundred milliliters or per one  
349 hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic  
350 amounts;

351 (5) Any material, compound, mixture, or preparation containing any of the following  
352 narcotic drugs or their salts, as set forth in subdivision (6) of this subsection; buprenorphine;

353 (6) Anabolic steroids. Any drug or hormonal substance, chemically and  
354 pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and  
355 dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is  
356 expressly intended for administration through implants to cattle or other nonhuman species and  
357 which has been approved by the Secretary of Health and Human Services for that administration.  
358 If any person prescribes, dispenses, or distributes such steroid for human use, such person shall  
359 be considered to have prescribed, dispensed, or distributed an anabolic steroid within the  
360 meaning of this [paragraph] **subdivision**. Unless specifically excepted or unless listed in another  
361 schedule, any material, compound, mixture or preparation containing any quantity of the  
362 following substances, including its salts, esters and ethers:

- 363 (a)  $3\beta,17$ -dihydroxy- $5\alpha$ -androstane;  
364 (b)  $3\alpha,17\beta$ -dihydroxy- $5\alpha$ -androstane;  
365 (c)  $5\alpha$ -androstan- $3,17$ -dione;  
366 (d) 1-androstenediol ( $3\beta,17\beta$ -dihydroxy- $5\alpha$ -androst-1-ene);  
367 (e) 1-androstenediol ( $3\alpha,17\beta$ -dihydroxy- $5\alpha$ -androst-1-ene);  
368 (f) 4-androstenediol ( $3\beta,17\beta$ -dihydroxy-androst-4-ene);  
369 (g) 5-androstenediol ( $3\beta,17\beta$ -dihydroxy-androst-5-ene);  
370 (h) 1-androstenedione ( $[5\alpha]$ -androst-1-en- $3,17$ -dione);  
371 (i) 4-androstenedione (androst-4-en- $3,17$ -dione);  
372 (j) 5-androstenedione (androst-5-en- $3,17$ -dione);  
373 (k) Bolasterone ( $7\alpha, 17\alpha$ -dimethyl- $17\beta$ -hydroxyandrost-4-en-3-one);  
374 (l) Boldenone ( $17\beta$ -hydroxyandrost-1,4,-diene-3-one);  
375 (m) Boldione;  
376 (n) Calusterone ( $7\beta, 17\alpha$ -dimethyl- $17\beta$ -hydroxyandrost-4-en-3-one);  
377 (o) Clostebol (4-chloro- $17\beta$ -hydroxyandrost-4-en-3-one);

- 378 (p) Dehydrochloromethyltestosterone (4-chloro-17 $\beta$ -hydroxy-17 $\alpha$ -methyl-androst-1,4-  
379 dien-3-one);
- 380 (q) Desoxymethyltestosterone;
- 381 (r)  $\Delta$ 1-dihydrotestosterone (a.k.a. '1-testosterone')(17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3-one);
- 382 (s) 4-dihydrotestosterone (17 $\beta$ -hydroxy-androstan-3-one);
- 383 (t) Drostanolone (17 $\beta$ -hydroxy-2 $\alpha$ -methyl-5 $\alpha$ -androstan-3-one);
- 384 (u) Ethylestrenol (17 $\alpha$ -ethyl-17 $\beta$ -hydroxyestr-4-ene);
- 385 (v) Fluoxymesterone (9-fluoro-17 $\alpha$ -methyl-11 $\beta$ ,17 $\beta$ -dihydroxyandrost-4-en-3-one);
- 386 (w) Formebolone (2-formyl-17 $\alpha$ -methyl-11 $\alpha$ ,17 $\beta$ -dihydroxyandrost-1,4-dien-3-one);
- 387 (x) Furazabol (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrostan[2,3-c]-furazan);
- 388 (y) 13 $\beta$ -ethyl-17 $\beta$ -hydroxygon-4-en-3-one;
- 389 (z) 4-hydroxytestosterone (4,17 $\beta$ -dihydroxy-androst-4-en-3-one);
- 390 (aa) 4-hydroxy-19-nortestosterone (4,17 $\beta$ -dihydroxy-estr-4-en-3-one);
- 391 (bb) Mestanolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-5-androstan-3-one);
- 392 (cc) Mesterolone (1 $\alpha$ -methyl-17 $\beta$ -hydroxy-[5 $\alpha$ ]-androstan-3-one);
- 393 (dd) Methandienone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrost-1,4-dien-3-one);
- 394 (ee) Methandriol (17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-5-ene);
- 395 (ff) Methenolone (1-methyl-17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3-one);
- 396 (gg) 17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane);
- 397 (hh) 17 $\alpha$ -methyl-3 $\alpha$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane);
- 398 (ii) 17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-4-ene;
- 399 (jj) 17 $\alpha$ -methyl-4-hydroxynandrolone (17 $\alpha$ -methyl-4-hydroxy-17 $\beta$ -hydroxyestr-4-en-3-  
400 one);
- 401 (kk) Methyldienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-4,9(10)-dien-3-one);
- 402 (ll) Methyltrienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-4,9-11-trien-3-one);
- 403 (mm) Methyltestosterone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrost-4-en-3-one);
- 404 (nn) Mibolerone (7 $\alpha$ ,17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyestr-4-en-3-one);
- 405 (oo) 17 $\alpha$ -methyl- $\Delta$ 1-dihydrotestosterone (17 $\beta$ -hydroxy-17 $\alpha$ -methyl-5 $\alpha$ -androst-1-en-3-  
406 one) (a.k.a. '17- $\alpha$ -methyl-1-testosterone');
- 407 (pp) Nandrolone (17 $\beta$ -hydroxyestr-4-ene-3-one);
- 408 (qq) 19-nor-4-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-4-ene);
- 409 (rr) 19-nor-4-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxyestr-4-ene);
- 410 (ss) 19-nor-4,9(10)-androstadienedione;
- 411 (tt) 19-nor-5-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-5-ene);
- 412 (uu) 19-nor-5-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxyestr-5-ene);
- 413 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);

- 414 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);  
415 (xx) Norbolethone (13 $\beta$ ,17 $\alpha$ -diethyl-17 $\beta$ -hydroxygon-4-en-3-one);  
416 (yy) Norclostebol (4-chloro-17 $\beta$ -hydroxyestr-4-en-3-one);  
417 (zz) Norethandrolone (17 $\alpha$ -ethyl-17 $\beta$ -hydroxyestr-4-en-3-one);  
418 (aaa) Normethandrolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestr-4-en-3-one);  
419 (bbb) Oxandrolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-2-oxa-[5 $\alpha$ ]-androstan-3-one);  
420 (ccc) Oxymesterone (17 $\alpha$ -methyl-4,17 $\beta$ -dihydroxyandrost-4-en-3-one);  
421 (ddd) Oxymethalone (17 $\alpha$ -methyl-2-hydroxymethylene-17 $\beta$ -hydroxy-[5 $\alpha$ ]-androstan-3-  
422 one);  
423 (eee) Stanozolol (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-[5 $\alpha$ ]-androst-2-eno[3,2-c]-pyrazole);  
424 (fff) Stenbolone (17 $\beta$ -hydroxy-2-methyl-[5 $\alpha$ ]-androst-1-en-3-one);  
425 (ggg) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);  
426 (hhh) Testosterone (17 $\beta$ -hydroxyandrost-4-en-3-one);  
427 (iii) Tetrahydrogestrinone (13 $\beta$ ,17 $\alpha$ -diethyl-17 $\beta$ -hydroxygon-4,9,11-trien-3-one);  
428 (jjj) Trenbolone (17 $\beta$ -hydroxyestr-4,9,11-trien-3-one);  
429 (kkk) Any salt, ester, or ether of a drug or substance described or listed in this  
430 subdivision, except an anabolic steroid which is expressly intended for administration through  
431 implants to cattle or other nonhuman species and which has been approved by the Secretary of  
432 Health and Human Services for that administration;
- 433 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a  
434 United States Food and Drug Administration approved drug product;
- 435 (8) The department of health and senior services may except by rule any compound,  
436 mixture, or preparation containing any stimulant or depressant substance listed in subdivisions  
437 (1) and (2) of this subsection from the application of all or any part of sections 195.010 to  
438 195.320 if the compound, mixture, or preparation contains one or more active medicinal  
439 ingredients not having a stimulant or depressant effect on the central nervous system, and if the  
440 admixtures are included therein in combinations, quantity, proportion, or concentration that  
441 vitiate the potential for abuse of the substances which have a stimulant or depressant effect on  
442 the central nervous system.
- 443 7. The department of health and senior services shall place a substance in Schedule IV  
444 if it finds that:
- 445 (1) The substance has a low potential for abuse relative to substances in Schedule III;  
446 (2) The substance has currently accepted medical use in treatment in the United States;  
447 and  
448 (3) Abuse of the substance may lead to limited physical dependence or psychological  
449 dependence relative to the substances in Schedule III.

450 8. The controlled substances listed in this subsection are included in Schedule IV:

451 (1) Any material, compound, mixture, or preparation containing any of the following  
452 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities  
453 as set forth below:

454 (a) Not more than one milligram of difenoxin and not less than twenty-five micrograms  
455 of atropine sulfate per dosage unit;

456 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-  
457 propionoxybutane);

458 (c) Any of the following limited quantities of narcotic drugs or their salts, which shall  
459 include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer  
460 upon the compound, mixture or preparation valuable medicinal qualities other than those  
461 possessed by the narcotic drug alone:

462 a. Not more than two hundred milligrams of codeine per one hundred milliliters or per  
463 one hundred grams;

464 b. Not more than one hundred milligrams of dihydrocodeine per one hundred milliliters  
465 or per one hundred grams;

466 c. Not more than one hundred milligrams of ethylmorphine per one hundred milliliters  
467 or per one hundred grams;

468 (2) Any material, compound, mixture or preparation containing any quantity of the  
469 following substances, including their salts, isomers, and salts of isomers whenever the existence  
470 of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

471 (a) Alprazolam;

472 (b) Barbital;

473 (c) Bromazepam;

474 (d) Camazepam;

475 (e) Chloral betaine;

476 (f) Chloral hydrate;

477 (g) Chlordiazepoxide;

478 (h) Clobazam;

479 (i) Clonazepam;

480 (j) Clorazepate;

481 (k) Clotiazepam;

482 (l) Cloxazolam;

483 (m) Delorazepam;

484 (n) Diazepam;

485 (o) Dichloralphenazone;

- 486 (p) Estazolam;
- 487 (q) Ethchlorvynol;
- 488 (r) Ethinamate;
- 489 (s) Ethyl loflazepate;
- 490 (t) Fludiazepam;
- 491 (u) Flunitrazepam;
- 492 (v) Flurazepam;
- 493 (w) Fospropofol;
- 494 (x) Halazepam;
- 495 (y) Haloxazolam;
- 496 (z) Ketazolam;
- 497 (aa) Loprazolam;
- 498 (bb) Lorazepam;
- 499 (cc) Lormetazepam;
- 500 (dd) Mebutamate;
- 501 (ee) Medazepam;
- 502 (ff) Meprobamate;
- 503 (gg) Methohexital;
- 504 (hh) Methylphenobarbital (mephobarbital);
- 505 (ii) Midazolam;
- 506 (jj) Nimetazepam;
- 507 (kk) Nitrazepam;
- 508 (ll) Nordiazepam;
- 509 (mm) Oxazepam;
- 510 (nn) Oxazolam;
- 511 (oo) Paraldehyde;
- 512 (pp) Petrichloral;
- 513 (qq) Phenobarbital;
- 514 (rr) Pinazepam;
- 515 (ss) Prazepam;
- 516 (tt) Quazepam;
- 517 (uu) Temazepam;
- 518 (vv) Tetrazepam;
- 519 (ww) Triazolam;
- 520 (xx) Zaleplon;
- 521 (yy) Zolpidem;

- 522 (zz) Zopiclone;
- 523 (3) Any material, compound, mixture, or preparation which contains any quantity of the  
524 following substance including its salts, isomers and salts of isomers whenever the existence of  
525 such salts, isomers and salts of isomers is possible: fenfluramine;
- 526 (4) Any material, compound, mixture or preparation containing any quantity of the  
527 following substances having a stimulant effect on the central nervous system, including their  
528 salts, isomers and salts of isomers:
- 529 (a) Cathine ((+)-norpseudoephedrine);
- 530 (b) Diethylpropion;
- 531 (c) Fencamfamin;
- 532 (d) Fenproporex;
- 533 (e) Mazindol;
- 534 (f) Mefenorex;
- 535 (g) Modafinil;
- 536 (h) Pemoline, including organometallic complexes and chelates thereof;
- 537 (i) Phentermine;
- 538 (j) Pipradrol;
- 539 (k) Sibutramine;
- 540 (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);
- 541 (5) Any material, compound, mixture or preparation containing any quantity of the  
542 following substance, including its salts:
- 543 (a) Butorphanol;
- 544 (b) Pentazocine;
- 545 (6) Ephedrine, its salts, optical isomers and salts of optical isomers, when the substance  
546 is the only active medicinal ingredient;
- 547 (7) The department of health and senior services may except by rule any compound,  
548 mixture, or preparation containing any depressant substance listed in subdivision (1) of this  
549 subsection from the application of all or any part of sections 195.010 to 195.320 if the  
550 compound, mixture, or preparation contains one or more active medicinal ingredients not having  
551 a depressant effect on the central nervous system, and if the admixtures are included therein in  
552 combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the  
553 substances which have a depressant effect on the central nervous system.
- 554 9. The department of health and senior services shall place a substance in Schedule V  
555 if it finds that:
- 556 (1) The substance has low potential for abuse relative to the controlled substances listed  
557 in Schedule IV;

558 (2) The substance has currently accepted medical use in treatment in the United States;  
559 and

560 (3) The substance has limited physical dependence or psychological dependence liability  
561 relative to the controlled substances listed in Schedule IV.

562 10. The controlled substances listed in this subsection are included in Schedule V:

563 (1) Any compound, mixture or preparation containing any of the following narcotic  
564 drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set  
565 forth below, which also contains one or more nonnarcotic active medicinal ingredients in  
566 sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal  
567 qualities other than those possessed by the narcotic drug alone:

568 (a) Not more than two and five-tenths milligrams of diphenoxylate and not less than  
569 twenty-five micrograms of atropine sulfate per dosage unit;

570 (b) Not more than one hundred milligrams of opium per one hundred milliliters or per  
571 one hundred grams;

572 (c) Not more than five-tenths milligram of difenoxin and not less than twenty-five  
573 micrograms of atropine sulfate per dosage unit;

574 (2) Any material, compound, mixture or preparation which contains any quantity of the  
575 following substance having a stimulant effect on the central nervous system including its salts,  
576 isomers and salts of isomers: pyrovalerone;

577 (3) Any compound, mixture, or preparation containing any detectable quantity of  
578 pseudoephedrine or its salts or optical isomers, or salts of optical isomers or any compound,  
579 mixture, or preparation containing any detectable quantity of ephedrine or its salts or optical  
580 isomers, or salts of optical isomers;

581 (4) Unless specifically exempted or excluded or unless listed in another schedule, any  
582 material, compound, mixture, or preparation which contains any quantity of the following  
583 substances having a depressant effect on the central nervous system, including its salts:

584 (a) Lacosamide;

585 (b) Pregabalin.

586 11. If any compound, mixture, or preparation as specified in subdivision (3) of  
587 subsection 10 of this section is dispensed, sold, or distributed in a pharmacy without a  
588 prescription:

589 (1) All packages of any compound, mixture, or preparation containing any detectable  
590 quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers or ephedrine,  
591 its salts or optical isomers, or salts of optical isomers, shall be offered for sale only from behind  
592 a pharmacy counter where the public is not permitted, and only by a registered pharmacist or  
593 registered pharmacy technician; and

594 (2) Any person purchasing, receiving or otherwise acquiring any compound, mixture,  
595 or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers,  
596 or salts of optical isomers or ephedrine, its salts or optical isomers, or salts of optical isomers  
597 shall be at least eighteen years of age; and

598 (3) The pharmacist, intern pharmacist, or registered pharmacy technician shall require  
599 any person, prior to their purchasing, receiving or otherwise acquiring such compound, mixture,  
600 or preparation to furnish suitable photo identification that is issued by a state or the federal  
601 government or a document that, with respect to identification, is considered acceptable and  
602 showing the date of birth of the person;

603 (4) The seller shall deliver the product directly into the custody of the purchaser.

604 12. Pharmacists, intern pharmacists, and registered pharmacy technicians shall  
605 implement and maintain an electronic log of each transaction. Such log shall include the  
606 following information:

607 (1) The name, address, and signature of the purchaser;

608 (2) The amount of the compound, mixture, or preparation purchased;

609 (3) The date and time of each purchase; and

610 (4) The name or initials of the pharmacist, intern pharmacist, or registered pharmacy  
611 technician who dispensed the compound, mixture, or preparation to the purchaser.

612 13. Each pharmacy shall submit information regarding sales of any compound, mixture,  
613 or preparation as specified in subdivision (3) of subsection 10 of this section in accordance with  
614 transmission methods and frequency established by the department by regulation;

615 14. No person shall dispense, sell, purchase, receive, or otherwise acquire quantities  
616 greater than those specified in this chapter.

617 15. All persons who dispense or offer for sale pseudoephedrine and ephedrine products  
618 in a pharmacy shall ensure that all such products are located only behind a pharmacy counter  
619 where the public is not permitted.

620 16. Any person who knowingly or recklessly violates the provisions of subsections 11  
621 to 15 of this section is guilty of a class A misdemeanor.

622 17. The scheduling of substances specified in subdivision (3) of subsection 10 of this  
623 section and subsections 11, 12, 14, and 15 of this section shall not apply to any compounds,  
624 mixtures, or preparations that are in liquid or liquid-filled gel capsule form or to any compound,  
625 mixture, or preparation specified in subdivision (3) of subsection 10 of this section which must  
626 be dispensed, sold, or distributed in a pharmacy pursuant to a prescription.

627 18. The manufacturer of a drug product or another interested party may apply with the  
628 department of health and senior services for an exemption from this section. The department of  
629 health and senior services may grant an exemption by rule from this section if the department

630 finds the drug product is not used in the illegal manufacture of methamphetamine or other  
631 controlled or dangerous substances. The department of health and senior services shall rely on  
632 reports from law enforcement and law enforcement evidentiary laboratories in determining if the  
633 proposed product can be used to manufacture illicit controlled substances.

634           19. The department of health and senior services shall revise and republish the schedules  
635 annually.

636           20. The department of health and senior services shall promulgate rules under chapter  
637 536 regarding the security and storage of Schedule V controlled substances, as described in  
638 subdivision (3) of subsection 10 of this section, for distributors as registered by the department  
639 of health and senior services.

640           21. Logs of transactions required to be kept and maintained by this section and section  
641 195.417 shall create a rebuttable presumption that the person whose name appears in the logs is  
642 the person whose transactions are recorded in the logs.

T